Antiretroviral treatment for HIV infection in developing countries: an attainable new paradigm.

Scaling up access to antiretroviral drugs (ARVs) for HIV-infected adults and children in developing countries can no longer be refused for medical or economic reasons, or on the grounds of inequality, lack of infrastructure, risk of viral resistance or alternative priorities. Access to ARVs is an appropriate, rational and cost-effective investment choice in developing countries.